Trial Profile
An observational study to evaluate effect of Canagliflozin (CA) on dose of other commonly co-administered antidiabetic, antihypertensive (AH) and lipid lowering drugs (AL) over a period of 12 months.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Cilnidipine; Gliclazide; Metformin; Rosuvastatin; Sitagliptin; Telmisartan; Valsartan
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 22 Jul 2018 New trial record
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association